Madras Diabetes Research Foundation and Russia's Almazov Centre sign MoU for diabetes research
The Madras Diabetes Research Foundation (MDRF) has signed a memorandum of understanding with the Almazov National Medical Research Centre in Saint Petersburg, Russia, to advance collaborative research in diabetes care.
A press release said the partnership would focus on developing new diagnostic and treatment strategies, particularly for gestational diabetes mellitus. It will also explore emerging areas such as artificial intelligence (AI) and precision medicine in diabetes management.
The MoU was signed by V. Mohan, Chairman, MDRF, and Evgeny Shlyakhto, Director-General of the Almazov Centre. The agreement includes joint research projects, academic exchanges, collaborative publications, and training programmes. Dr. Mohan said: 'This collaboration reflects our shared commitment to tackling diabetes through scientific innovation and global cooperation. AI and precision medicine offer exciting possibilities to improve care.'
Dr. Mohan also delivered a keynote on AI in diabetes at the 8th Saint Petersburg Medical Innovation Forum, held at the Almazov Centre. Joint research on gestational diabetes is already under way, with teams led by Polina V. Popova from Almazov and MDRF researchers, the press release added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
‘New medicines help reverse heart failure in 1 of 4 patients'
1 2 3 Nagpur: New medicines are proving so effective that in about 25% of patients battling heart failure, the heart's pumping power can be restored to normal. "Heart failure is no longer a hopeless condition. With newer medicines, around a quarter of heart failure cases are reversible. This means the heart's pumping capacity can be regained. Moreover, in about 50% of patients, we can now control heart failure very effectively," said Dr JC Mohan, a leading cardiologist in India and key speaker at the Annual ECHO Nagpur 2025 Conference. Dr Mohan explained that heart failure is different from a heart attack. A heart attack is a sudden event in which a blockage cuts off the blood supply to the heart muscles. Heart failure, on the other hand, develops over time when the heart's ability to pump blood becomes weak, making it hard for the body to get enough oxygen. "Nearly 1% of India's adult population — about one crore people — are living with heart failure. Unfortunately, it has a worse outcome than many cancers because it often goes unrecognised, underestimated, and untreated," Dr Mohan said. He cautioned that people with diabetes and high blood pressure are at higher risk and urged early detection through regular check-ups. "With modern medicines, patients can live six to eight years longer than before. The key is early diagnosis and proper treatment. Simple tests like an ECHO (heart ultrasound), ECG, and certain blood tests help us detect heart failure early and start treatment before it's too late," Dr Mohan added. Dr Vinod Vijan, former president of Lipid Association of India, also shared crucial advice: "Indians should aim for cholesterol levels at least 10 points lower than global standard values because we are genetically more prone to heart diseases," he said. Dr Shantanu Sengupta, programme director for ECHO Nagpur 2025, said the past two decades have witnessed a big change in people's awareness. "This is the 21st year of ECHO in Nagpur, and today, common people know about it. ECHO has become as routine as ECG for diagnosing heart problems. 2D and 3D ECHO tests are giving doctors excellent information to detect heart diseases early. Everyone above 40 years should include ECHO in their regular health check-ups," Dr Sengupta recommended. About Heart Failure - Heart failure is a condition in which the heart can't pump blood strongly enough to meet the body's needs - It's different from a heart attack, which is a sudden blockage in heart blood flow - Nearly 1 crore people in India live with heart failure, often undiagnosed - The prognosis is serious—worse than many cancers - New medicines can reverse heart failure in about 25% of patients, restoring heart pumping power
Economic Times
5 days ago
- Economic Times
Novo Nordisk's Wegovy enters India: Can this weight loss jab beat Mounjaro? Price, who can use it & how it works
Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy contains semaglutide, mimicking a hormone to control blood sugar and reduce hunger. Priced from Rs 17,345 to Rs 26,015 monthly, it showed significant weight loss in trials. Tired of too many ads? Remove Ads India's obesity market is growing fast Tired of too many ads? Remove Ads How Wegovy Works Wegovy India Price List Dose Monthly Price (Rs) Price Per Dose (Rs) 0.25 mg Rs 17,345 Rs 4,366 0.5 mg Rs 17,345 Rs 4,366 1 mg Rs 17,345 Rs 4,366 1.75 mg Rs 24,280 Rs 6,070 2.4 mg Rs 26,015 Rs 6,503 Mounjaro Dose Monthly Price (Rs) 2.5 mg Rs 14,000 5 mg Rs 17,500 Almost like weight loss surgery, but with a catch Wegovy vs Mounjaro: What's the Difference? Feature Wegovy (Semaglutide) Mounjaro (Tirzepatide) How it works Mimics GLP-1 hormone Acts on GLP-1 and GIP hormones Effect Lowers appetite, slows digestion Improves insulin and reduces appetite Approved for Weight loss Diabetes (off-label for weight loss) How to use Weekly injection via Flexpen Weekly injection via vial Price range Rs 17,345–Rs 26,015 Rs 14,000–Rs 17,500 In a big step for India's weight loss drug market, Danish pharmaceutical company Novo Nordisk has officially launched Wegovy , its much-talked-about weight loss injection. The company is now competing directly with Eli Lilly's popular drug, Mounjaro Wegovy is a once-a-week injection that comes in a pen-like device called FlexTouch. It's easy to use and doesn't require vials or syringes. According to Managing Director of Novo Nordisk India, Vikrant Shrotriya, the drug will be available in pharmacies across India by the end of June 2025, The Times of India has one of the world's highest numbers of people struggling with weight. Around 254 million people have general obesity and over 351 million suffer from belly fat-related issues. With the anti-obesity medicine market jumping from Rs 133 crore in 2021 to Rs 576 crore today (as per PharmaTrac), Novo Nordisk sees a huge said, 'Obesity is a chronic illness and a growing problem in India. Wegovy is easy to use and will be priced specially for Indian patients.'Wegovy contains a compound called semaglutide , which mimics a natural hormone in the body. This hormone helps control blood sugar, reduce hunger, slow digestion, and make you feel full for longer. While similar drugs like Ozempic are meant for diabetes, Wegovy is approved for long-term weight comes in a FlexTouch device, allowing users to adjust their weekly dose easily. Each monthly pack includes four needles. The medicine works on brain areas that manage appetite and food to Dr V. Mohan, a well-known diabetologist, 'Semaglutide not only helps in weight loss but also improves heart and inflammation markers. It's a strong option for Indian patients dealing with both obesity and rising heart risks.'For comparison, Eli Lilly's Mounjaro is slightly cheaper:Wegovy has shown very strong results. In global studies, people lost up to 15% of their weight on average, and some even lost 20%. It also helped lower the risk of heart attacks and strokes and improved liver the results are mostly maintained only if the person continues using the drug. If stopped, weight gain can return. Doctors also warn that muscle loss may happen over time, so people need to be regularly from TOI
India Today
6 days ago
- India Today
Wegovy weight-loss drug now in India: How it works and who should take it
Novo Nordisk, a Danish pharmaceutical company, has launched its weight-loss drug Wegovy in India. The drug, which contains semaglutide, works by regulating appetite and food intake, and is now the first medication in India approved for both long-term weight management and heart risk reduction in people who are overweight or WHAT EXACTLY IS WEGOVY, AND HOW DOES IT WORK?At its core, Wegovy is a once-a-week prescription-only injection that mimics a natural hormone in the body called GLP-1 (glucagon-like peptide-1). This hormone plays a key role in appetite regulation. When you take Wegovy, it binds to GLP-1 receptors in the brain, helping to reduce hunger, make you feel full sooner, lowers food cravings and helps control blood sugar biological mechanism makes it easier for people to stick to a lower-calorie diet without constantly feeling deprived—unlike traditional weight-loss methods that rely on sheer willpower THE SCIENCE BEHIND IT? The active ingredient in Wegovy is semaglutide, a compound also used in Novo Nordisk's type 2 diabetes drug Ozempic (not yet available in India). While Ozempic is meant for blood sugar control, Wegovy uses a higher dose of semaglutide (up to 2.4 mg) specifically for weight management and heart health. Wegovy is a once-a-week prescription-only injection that mimics a natural hormonein the body called GLP-1. () Clinical trials have shown that Wegovy, when combined with diet and physical activity, leads to:advertisementUp to 20% body weight reduction in 1 out of 3 people within about 68 weeks20% lower risk of major heart problems such as stroke, heart attack, and death related to cardiovascular disease, especially in people already living with heart conditions and obesityHOW IS WEGOVY TAKEN?Wegovy is administered using an easy-to-use injection pen once a week. It comes in five dosage strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 usually start with the lowest dose and gradually increase to the full dose of 2.4 mg under their doctor's MUCH DOES WEGOVY COST?The first three doses (0.25, 0.5, 1 mg) are priced at Rs 17,345 per month (about Rs 4,366 per week). The 1.7 mg is priced at Rs 24,280 per month and the 2.4 mg (full dose) costs Rs 26,015 for a company says this price structure is designed to make the drug more accessible as obesity cases rise across the THIS MATTERS FOR INDIAIndia has the third highest number of people living with obesity or overweight, according to a major 2023 study by the Indian Council of Medical Research and the Madras Diabetes Research Foundation. The report found that 254 million Indians, or nearly 29% of the population, are affected. The company says this price structure is designed to make the drug more accessible as obesity cases rise across the country. () Obesity is often misunderstood as a lifestyle issue, but experts say it's a chronic condition influenced by genetics, environment, biology, and mental health—not just food or exercise habits. It also increases the risk of over 200 diseases, including type 2 diabetes, heart disease, kidney and liver disorders, and certain SHOULD USE WEGOVY?Wegovy is a prescription-only drug meant for:Adults with a Body Mass Index (BMI) of 30 or higher, orAdults with a BMI of 27 or higher who also have a weight-related health conditionIt must be used under medical supervision, as it can cause side effects in some people, the company stated. "Obesity is not just a personal health concern, it's a national epidemic. Wegovy offers a proven, science-backed solution with the convenience of a user-friendly device. With India-specific pricing and the same cost for the first three doses, we are reinforcing our commitment to address the country's growing obesity burden," said Vikrant Shrotriya, Managing Director of Novo Nordisk like Wegovy and Mounjaro represent a new era in obesity treatment in India, offering hope to millions who struggle with weight and related health issues. By working with the body's natural hunger signals and showing benefits beyond just weight loss, it's more than a slimming aid—it's a chronic care always, people considering Wegovy should consult their doctor to understand whether it's the right fit for their health needs.- EndsMust Watch
